Tag: drug-coated balloons
The FLEX vessel prep system: working to extend time and improve...
This advertorial is sponsored by VentureMed Group.
Arteriovenous (AV) access is challenging and dialysis is hard on the body and the mind. It causes physical...
CX 2024 controversies programme to draw in global voices to ensure...
This year’s 2024 Chairing Cross (CX) Symposium (23–25 April, London, UK) will feature debates on the success of endovascular arteriovenous fistulas (AVFs) alongside patient...
History warns us against “optimistic exuberance” in drug-coated balloon trials
The importance of assessing clinical trial data in an objective, balanced way has been borne out by recent history in the vascular surgery space,...
Plain balloon first and drug-eluting balloon second? The role of DCBs...
Kate Steiner (Stevenage, UK) discusses existing clinical evidence on drug-coated balloons (DCBs) in the treatment of arteriovenous access stenosis—and outlines areas where further data...
IN.PACT AV DCB sustained “superior” effectiveness in subgroups with high reintervention...
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB; Medtronic) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of...
Concept Medical provides update on IMPRESSION trial to evaluate MagicTouch AVF
Concept Medical has provided an update on the progress of the IMPRESSION (sirolimus-coated balloon angioplasty versus plain balloon angioplasty in the treatment of dialysis access dysfunction)...
More mixed results for DCBs in AV access maintenance as evidence...
Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...